Hepatitis C among injecting drug users is two times higher in Stockholm, Sweden than in Rotterdam, the Netherlands

Substance Use and Misuse

Volumn 48, Issue 14, 2013, Pages 1469-1474

  Norden, Lillebil ^a   Van Veen, Maaike ^b   Lidman, Christer ^a   Todorov, Ivo ^c   Guarita, Bruno ^d   Kretzschmar, Mirjam ^b,e   Wiessing, Lucas ^d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c STOCKHOLM UNIVERSITY   (Sweden)

^d EUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION   (Portugal)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Injecting drug users; Needle and syringe exchange programs; Opiate substitution treatment.; Sharing needles or syringes or other paraphernalia

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DRUG ABUSE; DRUG USE; FEMALE; HEPATITIS C; HIGH RISK BEHAVIOR; HUMAN; MALE; MIDDLE AGED; NETHERLANDS; PREVALENCE; RISK FACTOR; STATISTICS; SUBSTANCE ABUSE; SWEDEN;

ADOLESCENT; ADULT; AGED; CROSS-SECTIONAL STUDIES; DRUG USERS; FEMALE; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; NEEDLE SHARING; NETHERLANDS; PREVALENCE; RISK FACTORS; RISK-TAKING; SUBSTANCE ABUSE, INTRAVENOUS; SWEDEN;

EID: 84887972271     PISSN: 10826084     EISSN: 15322491     Source Type: Journal    
DOI: 10.3109/10826084.2013.793356     Document Type: Article

References (18)

1. Bruandet, A., Lucidarme, D., Decoster, A., Ilef, D., Harbonnier, J., Jacob, C., et al. (2006). Incidence and risk factors of HCV infection in a cohort of intravenous drug users in the North and East of France. Rev Epidemiol Sante Publique, 54 Spec No 1:1S15-1S22
2. De Boer, I. M., Op de Coul, E. L. M., Beuker, R. J., de Zwart, O., Al Taqatqa,W., & van de Laar, M. J.W. (2004). Trends in HIVprevalentie en risicogedrag onder injecterende druggebruikers in Rotterdam, 1994-2002 [Trends in HIV prevalence and risk behavior among injecting drug users in Rotterdam, 1994-2002]. Nederlands Tijdschrift voor Geneeskunde, 148(47), 2325-2330
3. EMCDDA. (2008-2009). Figure INF-6. HCV antibody prevalence among injecting drug users-studies with national and sub national coverage Statistics and Country Data; Country Overview. Retrieved October 7, 2009, from www.emcdda.europa.eu
4. EMCDDA. (2010). Statistics and Country data. Retrieved August 25, 2010, from http://www.emcdda.europa.eu
5. Gowing, L.,Ali, R.,&White, J. (2000). Buprenorphine for the management of opioid withdrawal. Cochrane Database of Systematic Reviews, (3):CD002025
6. Lidman, C., Norden, L., Kåberg, M., Käll, K., Franck, J., Aleman, S., et al. (2009). Hepatitis C infection among injecting drug users in Stockholm, Sweden: Prevalence and gender. Scandinavian Journal of Infectious Diseases, 41, 679-684
7. Lucidarme, D., Bruandet, A., Ilef, D., Harbonnier, J., Jacob, C., Decoster, A., et al. (2004). Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France. Epidemiology & Infection, 132(4), 699-708
8. Maher, L., Li, J., Jalaludin, B., Chant,K.G.,&Kaldor, J.M. (2007). High hepatitis C incidence in new injecting drug users: A policy failuré Australian and New Zealand Journal of Public Health, 31(1), 30-35
9. Metzger, D. S., & Navaline, H. (2003). HIV prevention among injection drug users: The need for integrated models. Journal of Urban Health, 80(4 Suppl 3), iii59-66
10. Ministry of Health, Welfare and Sport. (2010). EU Drugs Strategy (2005-2012) endorsed by the Council in 2004, Council Document 15074/04
11. Norden, L., Kåberg, M., Käll, K., Franck, J., & Lidman, C. (2009). Knowledge of status and assessment of personal health consequences with hepatitis C are not enough to change risk behaviour among injecting drug users in Stockholm County, Sweden. Scandinavian Journal of Infectious Diseases, 41, 727-734
12. Rhodes, T., Davis, M., & Judd, A. (2004). Hepatitis C and its risk management among drug injectors in London: Renewing harm reduction in the context of uncertainty. Addiction, 99(5), 621-633
13. Schreuder, I., van der Sande, M. A., de Wit, M., Bongaerts, M., Boucher, C. A., Croes, E. A., et al. (2010). Seroprevalence of HIV, hepatitis b, and hepatitis c among opioid drug users on methadone treatment in the Netherlands. Harm Reduction Journal, 26(7), 25
14. Strauss, S. M., Astone-Twerell, J., Munoz-Plaza, C. E., Des Jarlais, D. C., Gwadz, M., Hagan, H., et al. (2007). Drug treatment program patients' hepatitis C virus (HCV) education needs and their use of available HCV education services. BMC Health Services Research, 7, 39
15. Swedish Government Proposition 6:30. (2005). Swedish National Action plan on Drugs 2006-2010. Retrieved from http://www.regeringen.se
16. Turner, J., Bansi, L., Gilson, R., Gazzard, B., Walsh, J., Pillay, D., et al. UK Collaborative HIV Cohort (UK CHIC) Study. (2009). The prevalence of hepatitis C virus (HCV) infection in HIVpositive individuals in the UK-Trends in HCV testing and the impact of HCV on HIV treatment outcomes. Journal of Viral Hepatitis, 17(8), 569-577. [Epub Oct. 13
17. van den Berg, C., Smit, C., Van Brussel, G., Coutinho, R., & Prins, M. (2007). Amsterdam Cohort. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: Evidence from the Amsterdam Cohort Studies among drug users. Addiction, 102(9), 1454-1462
18. van den Hoek, J. A., van Haastrecht, H. J., & Coutinho, R. A. (1989). Risk reduction among intravenous drug users in Amsterdam under the influence of AIDS. American Journal of Public Health, 79(10), 1355-1357